Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 + Chemo + Rivaroxaban in Advanced Pancreatic Cancer
NCT02921022Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2016
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of symptomatic thromboembolic (TE) events at 1 year. Started Oct 2016; status: active, not recruiting.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02921022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921022.